New stock news | New Element Pharmaceuticals files for a second time with the Hong Kong Stock Exchange.

According to the disclosure of the Hong Kong Stock Exchange on March 20th, Hangzhou New Element Pharmaceutical Co., Ltd. (referred to as New Element Pharmaceutical) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC as its exclusive sponsor. This is the company's second submission to the Hong Kong Stock Exchange. The prospectus shows that New Element Pharmaceutical was established in 2012 and is a biotechnology company focusing on developing therapies in the fields of metabolism, inflammation, and cardiovascular diseases.